Case report
A 55-year-old woman with a history of insulin-dependent diabetes mellitus, diabetic nephropathy, hypertension, and cerebrovascular disease, was admitted to hospital with a urinary tract infection. Following inpatient and subsequently outpatient treatment with ciprofloxacin, she was re-admitted with pseudomembranous colitis, necessitating a subtotal colectomy and end ileostomy formation. An initial 48-hour postoperative intensive care stay was uneventful. Five days later, the patient was referred to the critical care team by the surgical high dependency unit staff due to bradypnoea and mental obtundation. Drainage via the patient' s nasogastric tube had been between 3,000 and 5,000 mL per 24 hours following discharge from the intensive care unit. Arterial blood gas analysis revealed a severe metabolic alkalosis (pH 7.61, pCO 2 7.6 kPa, standard bicarbonate 56 mmol/L), which was attributed to the large volume losses from the upper gastrointestinal tract. Serum biochemical investigations were as follows: sodium 138 mmol/L, potassium 3.6 mmol/L, creatinine 320 µmol/L, urea 11.3 mmol/L, calcium (corrected for albumin) 1.89 mmol/L and phosphate 2.37 mmol/L. The patient was intubated and mechanically ventilated prior to abdominal imaging, which excluded mechanical intestinal obstruction, and re-admitted to intensive care.
Ongoing nasogastric losses totalled approximately four litres in 24 hours. The first 24 hours of critical care management consisted of fluid resuscitation (over 11 litres of a mixture of packed red blood cells, crystalloids and gelatin-based colloid were used) and the replacement of electrolytes including 180 mmol of potassium chloride and 20 mL of 10% calcium gluconate. Gastric acid secretion was suppressed with 50 mg ranitidine IV twice daily, and 40 mg omeprazole IV once daily. Acetazolamide 250 mg IV three times daily was commenced on admission to the intensive care unit in order to hasten correction of the alkalosis. Twenty-four hours after admission, an infusion of 0.1 M hydrochloric acid was commenced at 20 mL/h via a central venous catheter to correct the significant alkalaemia which persisted despite initial treatment measures and adjusting minute ventilation to provide a compensatory respiratory acidosis ( Table 1) . After three hours, the hydrochloric acid infusion rate was increased to 40 mL/h, and continued for a further 13 hours. A total of 580 mL of a 0.1 M solution were administered over 16 hours.
By 72 hours after admission, the acid-base state had normalised and the endotracheal tube was removed. Nasogastric losses had diminished significantly, and acetazolamide was discontinued. The subsequent intensive care course was complicated by high ileostomy outputs requiring treatment with octreotide, and the leak of stoma contents into the midline laparotomy wound. The patient remained in the acute hospital for a further two months due to recurrent intraabdominal collections, before being discharged to a community hospital for convalescence.
Discussion
The tight regulation of blood pH within the range 7.35-7.45 is a critical component of human homeostasis. Metabolic alkalosis is the most common acid-base abnormality in hospital practice, seen in 51% of patients with acid-base disturbances. 1 Severe alkalaemia is less common but of considerable importance, with a mortality rate of over 40%. 2, 3 Severe alkalaemia causes arteriolar vasoconstriction in the cerebral and coronary circulations, which may lead to an alteration in conscious level, seizures, impaired myocardial contractility and dysrhythmias. Hypokalaemia, which very frequently accompanies severe alkalaemia, may also promote dysrhythmias, as does the reduced ionised calcium level caused by the increased binding of calcium to albumin. These electrolyte abnormalities can also cause generalised muscle irritability, weakness and myoclonus. 4 Metabolic alkalosis causes compensatory alveolar hypoventilation via central mechanisms and also reduces the carotid body chemoreceptor response to hypoxia. While the resultant rise in PaCO 2 may prevent a lethal pH from developing, normal oxygen carriage is disrupted by alveolar hypoxia, atelectasis, impaired V/Q matching and a left-shift in the oxygen dissociation curve.
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Metabolic alkalosis is a common acid-base abnormality in hospitalised patients, though not frequently life-threatening. We present a case of severe metabolic alkalosis complicating colorectal surgery, which necessitated treatment with intravenous hydrochloric acid. The pathophysiology and treatment of severe metabolic alkalosis are reviewed, with an emphasis on the risks and benefits of hydrochloric acid use.
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Causes of metabolic alkalosis
A wide spectrum of disorders is responsible for the generation of metabolic alkalosis ( Table 2 ). Among these, gastrointestinal acid loss and the renal response to diuretics are most common. The gastric parietal cell forms hydrogen ions and bicarbonate from carbon dioxide and water via the enzyme carbonic anhydrase. A unique H + /K + ATPase transports hydrogen ions into the stomach lumen against a steep concentration gradient, in order to produce gastric secretions containing around 100 mmol/L hydrochloric acid, with smaller amounts of potassium and sodium chloride. An 'alkaline tide' of bicarbonate ions leaves the microcirculation of the gastric mucosa; however, under normal circumstances the neutralisation and subsequent reabsorption of gastric secretions by bicarbonate-rich pancreatic juice in the small bowel prevents the development of systemic alkalaemia. When gastric secretions are lost through vomiting or nasogastric suction, this homeostatic mechanism fails, and a hypochloraemic, hypokalaemic, metabolic alkalosis develops, associated with extra-cellular volume depletion.
A number of conditions cause metabolic alkalosis by potentiating one or more elements of the renin-angiotensinaldosterone (RAS) axis. Diuretics and volume depletion activate the RAS, and the action of angiotensin II on AT1 and AT2 receptors causes activation of bicarbonate-retaining and proton-secreting mechanisms along the length of the nephron. The enzymatic targets, predominantly the membrane bound Na + /HCO 3 co-transport pumps and Na + /H + exchange pumps in the proximal tubule, function in order to increase sodium and water absorption, thus maintaining intravascular volume at the expense of acid-base balance. Steroid excess and hyperaldosteronism cause increased renal acid loss via the mineralocorticoid receptor, primarily in the intercalated cells of the collecting duct, where sodium reabsorption is promoted while hydrogen ions are secreted in order to maintain electroneutrality. H + -ATPase plays a key role in this pathway. 5 Administration of alkali tends to cause a minimal and transient increase in pH in otherwise normal individuals. The kidney is extremely efficient at excreting bicarbonate and even administering 1,000 mmol/day of sodium bicarbonate does not precipitate significant alkalosis. Thus, for metabolic alkalosis to develop and be maintained, renal bicarbonate excretion must be impaired. The most important factors which prevent bicarbonate excretion, and the correction of metabolic alkalosis are: • Volume depletion This is the most common reason for the maintenance of metabolic alkalosis. Reduced renal perfusion causes a fall in glomerular filtration (preventing the passage of bicarbonate into the tubular fluid) and stimulates the RAS, resulting in sodium and bicarbonate absorption as described above.
• Hypochloraemia
The reabsorption of sodium requires the concurrent absorption of an anion to maintain electroneutrality. The nephron is less permeable to chloride than to bicarbonate, therefore when the chloride concentration in the glomerular filtrate is low, bicarbonate is preferentially reabsorbed with sodium. The intercalated cells of the collecting duct are able to excrete intracellular bicarbonate in exchange for filtered chloride. However, this process depends on a high lumento-cell chloride gradient. In addition, the collecting duct H + -ATPase passively secretes chloride ions to preserve electroneutrality. When the filtrate chloride concentration is low, chloride will tend to diffuse out of the cells of the collecting duct, accompanied by H + . Therefore hypochloraemia will tend to maintain metabolic alkalosis.
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• Hypokalaemia
Hypokalaemia perpetuates metabolic alkalosis via a number of mechanisms. As intracellular potassium moves to the extracellular space along a concentration gradient, hydrogen ions move intracellularly to maintain electroneutrality. This intracellular acidosis increases renal bicarbonate reabsorption, renal ammonia production (resulting in NH 4 + excretion), and impairs chloride reabsorption. The renal response to hypokalaemia includes activation of an apical H + /K + ATPase, which reduces urinary potassium loss at the expense of further hydrogen ion secretion. In common with acidaemia, patients with chronic kidney disease may be at particular risk of developing severe alkalaemia. Once metabolic alkalosis develops, the kidneys are unable to compensate through increased bicarbonate clearance. In this situation, the only compensation mechanism is hypoventilation, which has obvious limitations. 6
Treatment of metabolic alkalosis
Wherever possible, the precipitating cause of the alkalaemia should be addressed. In the case described, mechanical intestinal obstruction as the cause for excessive nasogastric losses was excluded radiologically. Treatment focused on resolution of the metabolic abnormalities in order to speed resumption of normal gastrointestinal motility. A number of treatment options are available for the correction of alkalaemia, ranging from simple fluid and electrolyte replacement, drug therapies and haemodialysis. Fluid and electrolyte replacement in the form of sodium and potassium chlorides allows repletion of extracellular volume and reduces the activity of the RAS. Correction of hypokalaemia and hypochloraemia also facilitates increased urinary excretion of bicarbonate. Published reports suggest such treatment may be successful even for severe alkalaemia. 7 There are, however, circumstances such as congestive cardiac failure, hepatic failure, renal failure, and chronic hyponatraemia in which such a strategy may be contraindicated.
The carbonic anhydrase inhibitor acetazolamide, corrects metabolic alkalosis by preventing the conversion of hydrogen and bicarbonate ions to carbon dioxide and water in proximal renal tubular cells, and on the luminal brush border. This results in the renal loss of sodium and bicarbonate. The optimum dose of acetazolamide for this indication is unclear; the findings of one study suggest that a single 500 mg dose IV may be as effective as a regular dose of 250 mg given six hourly. However, this report describes its use in patients ventilated for obstructive lung disease who developed metabolic alkalosis in response to hypercapnoea. 8 Ammonium chloride and arginine and lysine hydrochlorides have also been used to correct metabolic alkalosis. These compounds are metabolised to hydrochloric acid and urea by the liver, but may precipitate hepatic encephalopathy even in patients with normal liver function. 9 The use of arginine and lysine hydrochlorides can also lead to severe hyperkalaemia in the presence of renal impairment. They are now seldom used. Where gastric acid loss is the cause of metabolic alkalosis, the suppression of acid secretion by the administration of an H 2 receptor antagonist or proton pump inhibitor has been shown to be an effective treatment in various situations. 6, 10, 11 In patients with renal impairment, haemodialysis has been used successfully to correct metabolic alkalosis. A variety of techniques have been employed, including the use of acid dialysis and low bicarbonate dialysates. 12, 13 More recently, the use of normal bicarbonate dialysates with an infusion of 0.9% saline have also been shown to safely reverse metabolic alkalosis associated with acid loss. 6, 14 The most unusual aspect of the current case was the use of IV hydrochloric acid for the correction of alkalosis. This approach was first reported in 1955. 15 Published indications for use vary, with some reports describing hydrochloric acid use for any patient with a pH greater than 7.45 in the presence of hypercarbia. Other authors have suggested restricting use to persistent alkaloses refractory to conventional therapy, or where volume replacement and acetazolamide are contraindicated. It may be of particular value in the rapid correction of severe alkalaemia associated with hypoxia, where a putative mechanism of improvement in hypoxic pulmonary vasoconstriction and V/Q matching has been proposed. 16, 17 Two calculations of the total dose of hydrochloric acid required (in mmol) are in common use: 0.5 x body weight (kilograms) x base excess; and 0.2 x body weight (kilograms) x (103 -measured chloride), the extracellular chloride deficit.
A maximum infusion rate of 0.2 mmol/kg/h has been suggested, with frequent measurements of acid-base status to allow appropriate titration of the infusion. 18 In the patient we report, only a quarter of this maximum infusion rate was required. The safety of hydrochloric acid infusions was established in case series published in the 1970s and 1980s where few complications were apparent even with prolonged use of up to 17 days in one patient. 3, 19 However, since the initial reports of the safety of hydrochloric acid, a number of potential complications have come to light. The use of solutions more concentrated than 0.1 M has been associated with the degradation of vascular access devices and haemolysis. 20 While the majority of infusions have been administered through central venous catheters due to the risk of tissue necrosis in the event of extravasation, there have been two published cases of chest wall necrosis due to the extravasation of hydrochloric acid through malpositioned central venous catheters. 21, 22 It would seem prudent therefore to ensure that infusions are administered via the distal port of a continuously transduced and well-secured central venous catheter. Perhaps most concerning is a series of five patients treated at a single centre with a solution of 0.2 M hydrochloric acid, who suffered fatal cardiac arrests preceded by bradycardia, hypotension and refractory hypoxia within 140 minutes of initiation of the infusion. Subsequent postmortem examinations did not identify a cause of death. 23 The use of IV hydrochloric acid is infrequent in the UK, and in order to treat the patient described in this case report, it was necessary to obtain the solution from a hospital over 150 miles away. This resulted in a significant delay in commencing the infusion. Despite the delay, it was desirable to persist with the use of hydrochloric acid due to the lack of resolution of the alkalosis, and desire to achieve metabolic stability before further complications developed. Renal replacement therapy would have been a suitable alternative, but balancing the risks of further central venous access against hydrochloric acid use, we elected to proceed with the latter.
Summary
Key points: 1. Severe metabolic alkalosis is associated with significant mortality when pH exceeds 7.55. 2. The underlying cause of severe metabolic alkalosis should be rapidly identified, and addressed where possible. 3. The presence of hypovolaemia, hypochloraemia and hypokalaemia prevent an appropriate renal response to metabolic alkalosis and should be corrected. 4. Sodium and potassium chlorides are the electrolyte solutions of choice in correcting metabolic alkalosis. 5. In severe metabolic alkalosis, the use of intravenous hydrochloric acid may be lifesaving -particularly if cardiovascular or central nervous system abnormalities are present, or simple electrolyte solutions are contraindicated. 6. The use of IV hydrochloric acid requires particular attention to venous catheter positioning and security, and vigilance to the potential complications. Patients should be treated and monitored in an intensive care unit.
